AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25124510 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) added to psychopharmacological treatment
Number of subjects: 0
Study 25124510 — intervention group
Group type: COMPARATOR
Intervention: Brief structured group psychoeducational intervention added to psychopharmacological treatment
Number of subjects: 0
Study 25124510 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical management including psychopharmacological treatment
Number of subjects: 0
Study 21479698 — intervention group
Group type: EXPERIMENTAL
Intervention: KIR2DS1
Number of subjects: 110
Study 21479698 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DS4 (2DS4 003/4/6/7)
Number of subjects: 110
Study 21479698 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DL1
Number of subjects: 110
Study 19166627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions implemented in 5630 individuals
Number of subjects: 15005
Study 19166627 — intervention group
Group type: COMPARATOR
Intervention: Control group of 9375 individuals
Number of subjects: 15005
Study 17244451 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 1.0 mg once daily for 168 weeks
Number of subjects: 0
Study 17244451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16279289 — intervention group
Group type: EXPERIMENTAL
Intervention: Open trial design (no placebo)
Number of subjects: 180
Study 16279289 — intervention group
Group type: COMPARATOR
Intervention: Blinded, placebo-controlled design
Number of subjects: 180
Study 16279289 — intervention group
Group type: EXPERIMENTAL
Intervention: Open trial design
Number of subjects: 180
Study 16279289 — intervention group
Group type: EXPERIMENTAL
Intervention: Open trial no tablet group
Number of subjects: 180
Study 11673219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (O3) exposure (0.25 ppm x 2 h)
Number of subjects: 8
Study 11673219 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 8
Study 9412558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 IU/kg rhGH daily for 3 weeks
Number of subjects: 16
Study 9412558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8430402 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led education
Number of subjects: 15
Study 8430402 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led education
Number of subjects: 15
Study 8430402 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 15
Study 3113223 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nitroglycerin patch therapy for 7 days
Number of subjects: 0
Study 3113223 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour-daily intermittent nitroglycerin patch therapy for 7 days
Number of subjects: 0
Study 3113223 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study 29847426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular facet injections with bupivacaine and steroid
Number of subjects: 229
Study 29847426 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial branch blocks
Number of subjects: 229
Study 29847426 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 229
Study 26200198 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training program (6-week duration, specific to swing phase, high-load open-chain kinetic movements)
Number of subjects: 20
Study 26200198 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual track and field training, no additional eccentric exercises)
Number of subjects: 20
Study 23474641 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood sexual and physical abuse
Number of subjects: 0
Study 22492369 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA diet (high in vegetable n-6 PUFA)
Number of subjects: 67
Study 20357374 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Number of subjects: 50
Study 20357374 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 50
Study 18076538 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink
Number of subjects: 23
Study 18076538 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 23
Study 16214493 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraction times measured at stimulus intensity 10% of supramaximal stimulus (10% MS)
Number of subjects: 30
Study 16214493 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of type 1 muscle fibers measured at the surface of the muscle
Number of subjects: 30
Study 16214493 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of type 1 muscle fibers measured in the deep region of the muscle
Number of subjects: 30
Study 11943558 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone-guided therapy
Number of subjects: 69
Study 11943558 — intervention group
Group type: COMPARATOR
Intervention: Clinical management
Number of subjects: 69
Study 10634050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of bupivacaine, mepivacaine and hyaluronidase (sub-group M)
Number of subjects: 399
Study 10634050 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (sub-group B)
Number of subjects: 399
Study 10634050 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar blockade
Number of subjects: 399
Study 10634050 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar blockade
Number of subjects: 399
Study 7536861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 0
Study 7536861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Number of subjects: 0
Study 7536861 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone
Number of subjects: 0
Study 7536861 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0
Study 7536861 — intervention group
Group type: COMPARATOR
Intervention: GC-MS
Number of subjects: 0
Study 7536861 — intervention group
Group type: COMPARATOR
Intervention: Immunoassays (TDx, EMIT, ABUS, CAC)
Number of subjects: 0
Study 1974402 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 30
Study 1974402 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium
Number of subjects: 30
Study 6797132 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid‐carbohydrate‐electrolyte infusion
Number of subjects: 22
Study 6797132 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate‐electrolyte infusion
Number of subjects: 22
Study 31539599 — intervention group
Group type: EXPERIMENTAL
Intervention: Engage (Coping Skills Training and Acceptance and Commitment Therapy)
Number of subjects: 24
Study 30673062 — intervention group
Group type: EXPERIMENTAL
Intervention: IYP program plus HPS
Number of subjects: 126
Study 30673062 — intervention group
Group type: COMPARATOR
Intervention: IYP program alone
Number of subjects: 126
Study 28204740 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention by a physical therapist (n = 84)
Number of subjects: 181
Study 28204740 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary care provider (n = 97)
Number of subjects: 181
Study 25549933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (100% post-treatment expectations)
Number of subjects: 476
Study 25549933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (0% post-treatment expectations)
Number of subjects: 476
Study 25549933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (100% baseline expectations)
Number of subjects: 476
Study 25549933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (0% baseline expectations)
Number of subjects: 476
Study 25549933 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control group)
Number of subjects: 476
Study 24220287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) alone
Number of subjects: 432
Study 24220287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) + Mefloquine (MQ)
Number of subjects: 432
Study 24220287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 432
Study 24220287 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (CTX)
Number of subjects: 432
Study 20923463 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 0
Study 20923463 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 0
Study 20923463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 20923463 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol ointment
Number of subjects: 0
Study 20923463 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 20923463 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 19465858 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 19465858 — intervention group
Group type: COMPARATOR
Intervention: Conventional, nonbiologic pharmacotherapy
Number of subjects: 0
Study 17264176 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg/d
Number of subjects: 50
Study 15374727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential transdermal estrogen‐progestin therapy
Number of subjects: 0
Study 15374727 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplementation for 6 months
Number of subjects: 0
Study 11466135 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged QTc dispersion (> or = 70 msec)
Number of subjects: 330
Study 11466135 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased QTc dispersion and left ventricular hypertrophy on ECG
Number of subjects: 330
Study 11466135 — intervention group
Group type: EXPERIMENTAL
Intervention: QTcmin (the shortest QTc interval among the 12 leads of ECG)
Number of subjects: 330
Study 9736231 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training by a nurse (Group A)
Number of subjects: 72
Study 9736231 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training after individual instruction (Group A)
Number of subjects: 72
Study 9736231 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Turbuhaler and practice at home (Group A)
Number of subjects: 72
Study 9736231 — intervention group
Group type: COMPARATOR
Intervention: No individual training (Group B)
Number of subjects: 72
Study 8295841 — intervention group
Group type: EXPERIMENTAL
Intervention: Child behavioral information
Number of subjects: 108
Study 8295841 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental role information
Number of subjects: 108
Study 8295841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of child behavioral and parental role information
Number of subjects: 108
Study 3987783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol alone
Number of subjects: 24
Study 3987783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus indapamide
Number of subjects: 24
Study 3987783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus xipamide
Number of subjects: 24
Study 3987783 — intervention group
Group type: COMPARATOR
Intervention: Previous three drug regimens (beta blocker and two other antihypertensive agents)
Number of subjects: 24
Study 31908251 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative focused cardiac ultrasound (FOCUS)
Number of subjects: 800
Study 31908251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative FOCUS)
Number of subjects: 800
Study 28910848 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 µg)
Number of subjects: 199
Study 28910848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 27107394 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron tablet (ferrous sulfate, 200 mg)
Number of subjects: 1011
Study 27107394 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron infusion
Number of subjects: 1011
Study 27107394 — intervention group
Group type: COMPARATOR
Intervention: Dietary controls
Number of subjects: 1011
Study 24618837 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-7
Number of subjects: 108
Study 24618837 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-13
Number of subjects: 108
Study 24618837 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-13 booster
Number of subjects: 108
Study 22766415 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified prolonged exposure intervention (3 sessions, initiated in the emergency department)
Number of subjects: 137
Study 22766415 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control group
Number of subjects: 137
Study 20413516 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine (900 mg/day) for 12 weeks
Number of subjects: 82
Study 20413516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 18624629 — intervention group
Group type: EXPERIMENTAL
Intervention: Having at least 3 medical care visits in a 6-month period
Number of subjects: 316
Study 18624629 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 316
Study 17047160 — intervention group
Group type: COMPARATOR
Intervention: Insulin clamp at 5 mU x m(-2) x min(-1)
Number of subjects: 8
Study 17047160 — intervention group
Group type: COMPARATOR
Intervention: Insulin clamp at 30 mU x m(-2) x min(-1)
Number of subjects: 8
Study 17047160 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin clamp at 55 mU x m(-2) x min(-1)
Number of subjects: 8
Study 17047160 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin clamp at 105 mU x m(-2) x min(-1)
Number of subjects: 8
Study 15081627 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 34
Study 15081627 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 34
Study 10908888 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a) 30 mcg IM once weekly
Number of subjects: 160
Study 10908888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 8956922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracarotid amobarbital procedure (IAP) with 125 mg sodium amytal injection
Number of subjects: 56
Study 8956922 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Memory Score
Number of subjects: 56
Study 8956922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hemisphere performance
Number of subjects: 56
Study 1372470 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5‐fluorouracil
Number of subjects: 71
Study 1372470 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser alone
Number of subjects: 71
Study 1372470 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic interferon
Number of subjects: 71
Study 1372470 — intervention group
Group type: COMPARATOR
Intervention: Combined 5‐fluorouracil and laser
Number of subjects: 71
Study 1372470 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to interferon regimen (1 or 3 MIU)
Number of subjects: 71
Study 3937154 — intervention group
Group type: EXPERIMENTAL
Intervention: Single patient education strategy (clinic exit interview)
Number of subjects: 0
Study 3937154 — intervention group
Group type: EXPERIMENTAL
Intervention: Double patient education strategy (clinic exit interview + educational meeting with family)
Number of subjects: 0
Study 3937154 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple patient education strategy (clinic exit interview + educational meeting with family + small group sessions)
Number of subjects: 0
Study 3937154 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 0
Study 31320446 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide 1 mg, 2 mg, 3 mg, 4 mg once weekly
Number of subjects: 254
Study 31320446 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide ≥1 mg
Number of subjects: 254
Study 31320446 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide 3 mg, 4 mg once weekly
Number of subjects: 254
Study 31320446 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 1.8 mg daily
Number of subjects: 254
Study 31320446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 28705551 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PDT)
Number of subjects: 30
Study 28705551 — intervention group
Group type: COMPARATOR
Intervention: Control (PDC)
Number of subjects: 30
Study 28705551 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 30
Study 27903250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived xenograft with PAOO
Number of subjects: 33
Study 27903250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass with PAOO
Number of subjects: 33
Study 27903250 — intervention group
Group type: COMPARATOR
Intervention: Modified corticotomy (Control group)
Number of subjects: 33
Study 24678813 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin, 2 monthly doses (n = 18)
Number of subjects: 36
Study 24678813 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin, 3 monthly doses (n = 18)
Number of subjects: 36
Study 24678813 — intervention group
Group type: COMPARATOR
Intervention: Control group, no treatment (n = 32)
Number of subjects: 36
Study 22041453 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal or infant antiretroviral interventions offered after DSMB recommendation
Number of subjects: 67
Study 22041453 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard-of-care (control) arm
Number of subjects: 67
Study 20359401 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated, documentation-based clinical decision support system (ARI Smart Form)
Number of subjects: 21961
Study 20359401 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21961
Study 17180572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration therapy only
Number of subjects: 424
Study 17180572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis once
Number of subjects: 424
Study 17180572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine
Number of subjects: 424
Study 17180572 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 424
Study 17180572 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated creatinine at 30-60 days
Number of subjects: 424
Study 15509041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive plaster of diclofenac epolamine (Flector Plaster)
Number of subjects: 0
Study 15509041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11724094 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 9630824 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 1 gm mycophenolate mofetil
Number of subjects: 5
Study 7524456 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 7524456 — intervention group
Group type: COMPARATOR
Intervention: High-dose thromboplastin
Number of subjects: 0
Study 7524456 — intervention group
Group type: COMPARATOR
Intervention: High-dose thrombin
Number of subjects: 0
Study 7524456 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated clotting time
Number of subjects: 0
Study 7524456 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thromboplastin and high-dose thrombin measurements
Number of subjects: 0
Study 3584744 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 61
Study 3584744 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (50 micrograms per actuation)
Number of subjects: 61
Study 31972655 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam continuous intravenous infusion (5 mg/min for 5 min, 3 mg/min for 15 min, 1 mg/min for 15 min)
Number of subjects: 20
Study 31972655 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam continuous intravenous infusion
Number of subjects: 20
Study 29548834 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized oral consent and written information sheet (Group 2)
Number of subjects: 28
Study 29548834 — intervention group
Group type: COMPARATOR
Intervention: Standardized oral informed consent (Group 1)
Number of subjects: 28
Study 27501080 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational-level occupational health intervention
Number of subjects: 196
Study 27501080 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 196
Study 24290575 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (open surgery)
Number of subjects: 1018
Study 24290575 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 1018
Study 23882695 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion therapy for amblyopia (6 hours/day in MOTAS; randomized to 6 or 12 hours/day in ROTAS)
Number of subjects: 152
Study 23882695 — intervention group
Group type: COMPARATOR
Intervention: Occlusion therapy on weekends
Number of subjects: 152
Study 23882695 — intervention group
Group type: COMPARATOR
Intervention: Occlusion therapy with less frequent attendance
Number of subjects: 152
Study 23882695 — intervention group
Group type: COMPARATOR
Intervention: Occlusion therapy with prolonged treatment duration
Number of subjects: 152
Study 23882695 — intervention group
Group type: EXPERIMENTAL
Intervention: Different subpopulations of patch day doses
Number of subjects: 152
Study 20667550 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtelephonic electrocardiogram (TTECG) monitoring
Number of subjects: 92
Study 20667550 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiogram and 24-hour Holter monitoring
Number of subjects: 92
Study 20667550 — intervention group
Group type: EXPERIMENTAL
Intervention: TTECG monitoring
Number of subjects: 92
Study 18982782 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI (5 ng L(‐1) remifentanil, 2.8 microg mL(‐1) propofol)
Number of subjects: 44
Study 18982782 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (8%)
Number of subjects: 44
Study 17083356 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrimp-derived glucosamine (1,500 mg)
Number of subjects: 15
Study 17083356 — intervention group
Group type: COMPARATOR
Intervention: Synthetic glucosamine (1,500 mg)
Number of subjects: 15